Guidelines for vitamin D prescription in dialysis patients;La prescription de vitamine D chez le patient dialysé en pratique clinique

Nephrologie et Therapeutique

Volumn 5, Issue 6, 2009, Pages 520-532

  Jean, Guillaume ^a   Lafage Proust, Marie Hélène ^b   Massy, Ziad A ^c   Drüeke, Tilman B ^d  

^a Centre de Rein Artificiel de Tassin   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Chronic kidney disease; Dialysis; Mineral metabolism; Pharmacology; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

ALFA; ALFACALCIDOL; CALCIFEDIOL; CALCITRIOL; COLECALCIFEROL; ERGOCALCIFEROL; UN ALFA; UNCLASSIFIED DRUG; UVEDOSE; UVESTEROL; VITAMIN D; VITAMIN D3 BON; ZYMA D; VITAMIN;

AUTOIMMUNE DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DRUG MECHANISM; FALLING; FRACTURE; HEMODIALYSIS PATIENT; HUMAN; MORTALITY; NEOPLASM; PATHOPHYSIOLOGY; PRESCRIPTION; RISK BENEFIT ANALYSIS; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SHORT SURVEY; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; DECISION TREE; METABOLISM; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; REVIEW;

DECISION TREES; HUMANS; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 71549135870     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2009.07.010     Document Type: Short Survey

References (78)

1. Bouillon R., Carmeliet G., Verlinden L., van Etten E., Verstuyf A., Luderer H.F., et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 29 6 (2008) 726-776
2. Nykjaer A., Dragun D., Walther D., Vorum H., Jacobsen C., Herz J., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96 (1999) 507-515
3. Hewison M., Zehnder D., Bland R., and Stewart P.M. 1-alpha-hydroxylase and the action of vitamin D. J Mol Endocrinol 25 (2000) 141-148
4. Dusso A.S., Finch J., Brown A., Ritter C., Delmez J., Schreiner G., et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 72 (1991) 157-164
5. Lambert P.W., Stern P.H., Avioli R.C., Brackett N.C., Turner R.T., Greene A., et al. Evidence for extrarenal production of 1 alpha, 25-dihydroxyvitamin D in man. J Clin Invest 69 (1982) 722-725
6. Van Driel M., Koedam M., Buurman C.J., Hewison M., Chiba H., Uitterlinden A.G., et al. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J 20 13 (2006) 2417-2419
7. Atkins G.J., Anderson P.H., Findlay D.M., Welldon K.J., Vincent C., Zannettino A.C., et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha 25-dihydroxyvitamin D3. Bone 40 6 (2007) 1517-1528
8. Bouillon R. Vitamin D: from photosynthesis, metabolism and action to clinical applications. In: De Groot L.J., and Jameson J.L. (Eds). Endocrinology 2 (2005), Elsevier Saunders, Philadelphia 1435-1463
9. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1 alpha hydroxylase in the classical and nonclassical actions of 1,25-dihydroxyvitamin D(3). Semin Dial 20 (2007) 316-324
10. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80 (2004) 1678S-16788S
11. Ritter C.S., Armbrecht H.J., Slatopolsky E., and Brown A.J. 25-hydroxyvitamin D3 suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 70 (2006) 654-659
12. Reichel H., Koeffler H.P., and Norman A.W. The role of the vitamin D endocrine system in health and disease. N Engl J Med 320 (1989) 980-991
13. Zeitz U., Weber K., Soegiarto D.W., Wolf E., Balling R., and Erben R.G. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 17 3 (2003) 509-511
14. Uitterlinden A.G., Fang Y., Van Meurs J.B., Pols H.A., and Van Leeuwen J.P. Genetics and biology of vitamin D receptor polymorphisms. Gene 338 2 (2004) 143-156
15. Valdivielso J.M., and Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 371 1-2 (2006) 1-12
16. Huhtakangas J.A., Olivera C.J., Bishop J.E., Zanello L.P., and Norman A.W. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1-25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol 18 (2004) 2660-2671
17. Norman A.W., Okamura W.H., Hammond M.W., Bishop J.E., Dormanen M.C., Bouillon R., et al. Comparison of 6-s-cis and 6-s-trans locked analogs of 1,25(OH)2-vitamin D3 indicates that the 6-s-cis conformation is preferred for rapid nongenomic biological responses and that neither 6-s-cis nor 6-s-trans locked analogs are preferred for genomic biological responses. Mol Endocrinol 11 (1997) 1518-1531
18. Schacht E., Richy F., and Reginster J.Y. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact 5 3 (2005) 273-284
19. Wilkins C.H., Sheline Y.I., Roe C.M., Birge S.J., and Morris J.C. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry 14 (2006) 1032-1040
20. Visser M., Deeg D.J., Puts M.T., Seidell J.C., and Lips P. Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr 84 (2006) 616-622
21. Van Cromphaut S.J., Dewerchin M., Hoenderop J.G., Stockmans I., Van Herck E., Kato S., et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci U S A 98 (2001) 13324-13329
22. Fujita H., Sugimoto K., Inatomi S., Maeda T., Osanai M., Uchiyama Y., et al. Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Calcium absorption between enterocytes. Mol Biol Cell 19 (2008) 1912-1921
23. Prié D., Torres P.U., and Friedlander G. Latest findings in phosphate homeostasis. Kidney Int (2009) 4
24. Razzaque M.S., and Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 194 (2007) 1-10
25. Li Y.C., Pirro A.E., Amling M., Delling G., Baron R., Bronson R., et al. Proc Natl Acad Sci U S A 94 (1997) 9831-9835
26. Masuyama R., Stockmans I., Torrekens S., Van Looveren R., Maes C., Carmeliet P., et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 116 12 (2006) 3150-3159
27. Drissi H., Pouliot A., Koolloos C., Stein J.L., Lian J.B., Stein G.S., et al. 1, 25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 274 2 (2002) 323-333
28. Sooy K., Sabbagh Y., and Demay M.B. Osteoblasts lacking the vitamin D receptor display enhanced osteogenic potential in vitro. J Cell Biochem (2005) 9481-9487
29. Tanaka H., and Seino Y. Direct action of 1,25-dihydroxyvitamin D on bone: VDRKO bone shows excessive bone formation in normal mineral condition. J Steroid Biochem Mol Biol (2004) 89-90 343-345
30. Gardiner E.M., Baldock P.A., Thomas G.P., Sims N.A., Henderson N.K., Hollis B., et al. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J 14 13 (2000 t) 1908-1916
31. Jurutka P.W., Bartik L., Whitfield G.K., Mathern D.R., Barthel T.K., Gurevich M., et al. Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action and novel nutritional ligands. J Bone Miner Res 22 Suppl 2 (2007) V2-10
32. Drueke TB. Hyperparathyroidism in chronic kidney disease. In: Arnold A, ed. Diseases of Bone and Mineral Metabolism: http://www.endotext.org/parathyroid/parathyroid6/parathyroidframe6.htm 2006 [consulté du 7 au 10 mai 2008].
33. Slatopolsky E., Brown A., and Dusso A. Calcium, phosphorus and vitamin D disorders in uremia. Contrib Nephrol 149 (2005) 261-271
34. Hsu C.H., Vanholder R., Patel S., De Smet R.R., Sandra P., and Ringoir S.M. Subfractions in uremic plasma ultrafiltrate inhibit calcitriol metabolism. Kidney Int 40 (1991) 868-873
35. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18 9 (2007) 2600-2608
36. Carter G.D., Carter C.R., Gunter E., Jones J., Jones G., Makin H.L., et al. Measurement of vitamin D metabolites: an international perspective on methodology and clinical interpretation. J Steroid Biochem Mol Biol 89-90 (2004) 467-471
37. Binkley N., Krueger D., Cowgill C.S., Plum L., Lake E., Hansen K.E., et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 89 (2004) 3152-3157
38. Hypponen E., Turner S., Cumberland P., Power C., and Gibb I. Serum 25-hydroxyvitamin D measurement in a large population survey with statistical harmonization of assay variation to an international standard. J Clin Endocrinol Metab 92 (2007) 4615-4622
39. Levin A., Bakris G.L., Molitch M., Smulders M., Tian J., Williams L.A., et al. Prevalence of abnormal serum vitamin D, PTH, calcium and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71 (2007) 31-38
40. Nesby-O'Dell S., Scanlon K.S., Cogswell M.E., Gillespie C., Hollis B.W., Looker A.C., et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 76 (2002) 187-192
41. LaClair R.E., Hellman R.N., Karp S.L., Kraus M., Ofner S., Li Q., et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45 (2005) 1026-1033
42. Khan S. Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease. Am J Med Sci 333 (2007) 201-207
43. Ghazali A., Fardellone P., Pruna A., Atik A., Achard J.M., Oprisiu R., et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?. Kidney Int 55 (1999) 2169-2177
44. Coen G., Mantella D., Manni M., Balducci A., Nofroni I., Sardella D., et al. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 68 (2005) 1840-1848
45. Wolf M., Shah A., Gutierrez O., Ankers E., Monroy M., Tamez H., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72 (2007) 1004-1013
46. Kalantar-Zadeh K., Kuwae N., Regidor D.L., Kovesdy C.P., Kilpatrick R.D., Shinaberger C.S., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 (2006) 771-780
47. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., and Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349 (2003) 446-456
48. Fissell R.B., Bragg-Gresham J.L., Gillespie B.W., Goodkin D.A., Bommer J., Saito A., et al. International variation in vitamin prescription and association with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 (2004) 293-299
49. Wilson C.W., Wingfield W.L., and Toone Jr. E.C. Vitamin D poisoning with metastatic calcification; report of a case and review of the mechanism of intoxication. Am J Med 14 (1953) 116-123
50. Lamm M., and Neuman W.F. On the role of vitamin D in calcification. JAMA 66 (1958) 204-209
51. Scarpelli D.G., Tremblay G., and Pearse A.G. A comparative cytochemical and cytologic study of vitamin D induced nephrocalcinosis. Am J Pathol 36 (1960) 331-353
52. Hoppe B., Gnehm H.E., Wopmann M., Neuhaus T., Willi U., and Leumann E. Vitamin D poisoning in infants: a preventable cause of hypercalciuria and nephrocalcinosis. Schweiz Med Wochenschr 122 (1992) 257-262
53. Besbas N., Oner A., Akhan O., Saatci U., Bakkaloglu A., and Topaloglu R. Nephrocalcinosis due to vitamin D intoxication. Turk J Pediatr 31 (1989) 239-244
54. Mallick N.P., and Berlyne G.M. Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure. Lancet 2 (1968) 1316-1320
55. Boaz M., Weinstein T., Matas Z., Green, and Smetana S. Peripheral vascular disease and serum phosphorus in hemodialysis: a nested case-control study. Clin Nephrol 63 (2005) 98-105
56. Wu-Wong J.R., Noonan W., Ma J., Dixon D., Nakane M., Bolin A.L., et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther 318 (2006) 90-98
57. Zittermann A., Schleithoff S.S., and Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol 18 (2007) 41-46
58. Watson K.E., Abrolat M.L., Malone L.L., Hoeg J.M., Doherty T., Detrano R., et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96 (1997) 1755-1760
59. London G.M., Guerin A.P., Verbeke F.H., Pannier B., Boutouyrie P., Marchais S.J., et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18 (2007) 613-620
60. Raggi P., Boulay A., Chasan-Taber S., Amin N., Dillon M., Burke S.K., et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?. J Am Coll Cardiol 39 (2002) 695-701
61. London G.M., Marty C., Marchais S.J., Guerin A.P., Metivier F., and de Vernejoul M.C. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15 (2004) 1943-1951
62. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 88 2 (2008) 582S-586S
63. Jean G., Terrat J.C., Vanel T., Hurot J.M., Lorriaux C., Mayor B., et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 110 1 (2008) c58-65
64. Aloia J.F., Vaswani A., Yeh J.K., Ellis K., Yasumura S., and Cohn S.H. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 84 (1988) 401-408
65. Mathew S., Lund R.J., Chaudhary L.R., Geurs T., and Hruska K.A. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19 8 (2008) 1509-1519
66. Zittermann A., Schleithoff S.S., and Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol 18 (2007) 41-46
67. Shroff R., Egerton M., Bridel M., Shah V., Donald A.E., Cole T.J., et al. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 19 6 (2008) 1239-1246
68. Barreto DV, Barreto FC, Liabeuf S, et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Nephrol (in press).
69. Eknoyan G., Levin A., and Levin N.W. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (2003) 1-201
70. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69 (2006) 1945-1953
71. Chapuy M.C., Preziosi P., Maamer M., Arnaud S., Galan P., Hercberg S., et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7 (1997) 439-443
72. Hernandez J.D., Wesseling K., Boechat M.I., Gales B., and Salusky I.B. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol. Nat Clin Pract Nephrol 3 4 (2007) 227-232
73. Horst R.L., Littledike E.T., Riley J.L., and Napoli J.L. Quantitation of vitamin D and its metabolites and their plasma concentrations in five species of animals. Anal Biochem 116 (1981) 189-203
74. Holick M.F., Biancuzzo R.M., Chen T.C., Klein E.K., Young A., Bibuld D., et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 93 (2008) 677-681
75. Romagnoli E., Mascia M.L., Cipriani C., Fassino V., Mazzei F., D'Erasmo E., et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab 93 8 (2008) 3015-3020
76. Mistretta V.I., Delanaye P., Chapelle J.P., Souberbielle J.C., and Cavalier E. Vitamin D2 or vitamin D3?. Rev Med Interne 29 10 (2008) 815-820
77. Armas L.A., Hollis B.W., and Heaney R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89 (2004) 5387-5391
78. Holick M.F. Vitamin D deficiency. N Engl J Med 357 (2007) 266-281